Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead Sciences reports positive data from Cayston trial

Gilead Sciences reports positive data from Cayston trial

22nd June 2010

Gilead Sciences has published new clinical trial data illustrating the advantages of Cayston, its inhalation-based antibiotic treatment for cystic fibrosis sufferers with Pseudomonas aeruginosa.

According to the results of the phase III study, the drug was able to demonstrate non-inferiority to tobramycin inhalation solution in terms of mean percent change in forced expiratory volume in one second per cent predicted following 28 days of treatment.

This mean the Gilead therapy was able to meet one of its co-primary endpoints in the trial, while positive safety data was also recorded.

Dr Norbert Bischofberger, Gilead’s executive vice-president of research and development and chief scientific officer, said there was a “significant unmet medical need” for a new treatment in this category.

He said: “Given the chronic nature of pseudomonal infection and the potential for antibiotic resistance, it is important that cystic fibrosis patients have multiple treatment options.”

Earlier this month, the company announced the appointment of Dr John McHutchison as its liver disease therapeutics division’s new senior vice-president.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.